7,654.50

+40.50

+0.53%

52,132.00

+214.00

+0.41%

28,820.50

+286.50

+1.00%

Russell 2000 Futures

2,839.40

+18.10

+0.64%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,921.30

+22.40

+0.57%

78,340.78

+575.79

+0.74%

Crude Oil Dec 26

100.23

-3.89

-3.74%

US Private Equity

10,850.63

-82.20

-0.75%

NYSE American - BOATS Real Time Price USD

AEON Biopharma, Inc. (AEON)

0.2740 -0.0200 (-6.80%)

At close: October 30 at 4:00:00 PM EDT

0.2875 +0.0135 (+4.93%)

Overnight: 12:21:08 AM EST

Loading Chart for AEON

Chart Range Bar

Interval:

In partnership with ChartIQ

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Mobilize your Website

View Site in Mobile | Classic

Share by: